Questcor Pharmaceuticals Inc. (QCOR) announced Tuesday morning that it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis.
Questcor Pharmaceuticals gapped open sharply higher Tuesday, but gradually gave back gains over the course of the trading session. Shares ended the day higher by 5.40 at $42.11, with volume at over an 8-month high. The stock finished at nearly a 1-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.